Literature DB >> 29902495

Gonococcal MtrE and its surface-expressed Loop 2 are immunogenic and elicit bactericidal antibodies.

Shuyi Wang1, Juan Xue1, Ping Lu1, Chunshan Ni1, Hao Cheng2, Rui Han2, Stijn van der Veen3.   

Abstract

OBJECTIVES: The rise in multidrug resistant Neisseria gonorrhoeae poses a threat to healthcare, while the development of an effective vaccine has remained elusive due to antigenic and phase variability of surface-expressed proteins. In the current study, we identified a fully conserved surface expressed protein and characterized its suitability as a vaccine antigen.
METHODS: An in silico approach was used to predict surface-expressed proteins and analyze sequence conservation and phase variability. The most conserved protein and its surface-exposed Loop 2, which was displayed as both a structural and linear epitope on the oligomerization domain of C4b binding protein, were used to immunize mice. Immunogenicity was subsequently analyzed by determination of antibody titers and serum bactericidal activity.
RESULTS: MtrE was identified as one of the most conserved surface-expressed proteins. Furthermore, MtrE and both Loop 2-containing fusion proteins elicited high protein-specific antibody titers and particularly the two Loop 2 fusion proteins showed high anti-Loop 2 titers. In addition, antibodies raised against all three proteins were able to recognize MtrE expressed on the surface of N. gonorrhoeae and showed high MtrE-dependent bactericidal activity.
CONCLUSIONS: Our results show that MtrE and Loop 2 are promising novel conserved surface-expressed antigens for vaccine development against N. gonorrhoeae.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  C4bp; Epitope display; IMX315; Loop 2; MtrCDE; MtrE; Neisseria gonorrhoeae; SBA; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29902495     DOI: 10.1016/j.jinf.2018.06.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.

Authors:  Kathryn A Matthias; Kristie L Connolly; Afrin A Begum; Ann E Jerse; Andrew N Macintyre; Gregory D Sempowski; Margaret C Bash
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

Review 2.  Sexually Transmitted Neisseria gonorrhoeae Infections-Update on Drug Treatment and Vaccine Development.

Authors:  Amber Jefferson; Amanda Smith; Pius S Fasinu; Dorothea K Thompson
Journal:  Medicines (Basel)       Date:  2021-02-05

3.  The MtrCDE Efflux Pump Contributes to Survival of Neisseria gonorrhoeae From Human Neutrophils and Their Antimicrobial Components.

Authors:  Jonathan W Handing; Stephanie A Ragland; Urmila V Bharathan; Alison K Criss
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

4.  Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.

Authors:  Sunita Gulati; Michael W Pennington; Andrzej Czerwinski; Darrick Carter; Bo Zheng; Nancy A Nowak; Rosane B DeOliveira; Jutamas Shaughnessy; George W Reed; Sanjay Ram; Peter A Rice
Journal:  mBio       Date:  2019-11-05       Impact factor: 7.867

Review 5.  Progress Toward a Gonococcal Vaccine: The Way Forward.

Authors:  Michael W Russell; Ann E Jerse; Scott D Gray-Owen
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

6.  Impact of the gonococcal FC428 penA allele 60.001 on ceftriaxone resistance and biological fitness.

Authors:  Ke Zhou; Shao-Chun Chen; Fan Yang; Stijn van der Veen; Yue-Ping Yin
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

7.  Adaptation to the cervical environment is associated with increased antibiotic susceptibility in Neisseria gonorrhoeae.

Authors:  Kevin C Ma; Tatum D Mortimer; Allison L Hicks; Nicole E Wheeler; Leonor Sánchez-Busó; Daniel Golparian; George Taiaroa; Daniel H F Rubin; Yi Wang; Deborah A Williamson; Magnus Unemo; Simon R Harris; Yonatan H Grad
Journal:  Nat Commun       Date:  2020-08-17       Impact factor: 14.919

Review 8.  Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.

Authors:  Eric Y Lin; Paul C Adamson; Jeffrey D Klausner
Journal:  Drugs       Date:  2021-06-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.